poisar

Stocks · News reference

Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW

Benzinga Newsdesk

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

    The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

    IPSEYEVMNABBVPFELLY
  2. Adria Cimino

    Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It

    Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

    VRTXLLYABBVBRK.ABRK.B